Cxbladder is a family of non-invasive molecular diagnostic laboratory tests optimized to help you assess the probability that your patient has bladder cancer, giving you actionable results that can make a meaningful difference in their treatment.


More reliable and objective than many other urine-based tests, Cxbladder utilizes high sensitivity and Negative Predictive Value to provide accurate results.


Cxbladder provides actionable results to facilitate the early detection of bladder cancer by either helping to rule out the disease or to complement other diagnostic procedures and tests.


Non-invasive and pain free, Cxbladder provides a complete sampling system for collection of the patient’s urine sample and shipment to our laboratory.


Over ten years of research has identified five specific messenger RNA (mRNA) biomarkers that represent a bladder cancer signature. Cxbladder has been validated by a multicenter clinical study published in a highly respected peer reviewed journal.

Clinical Applications

Cxbladder gives you actionable results that can make a meaningful difference in your patient's diagnosis and treatment.

  • References

    Cxbladder was developed by a company whose passion and focus is cancer diagnostics and prognostics to improve patient outcomes. See our full list of clinical publications.

    Pacific Edge is responsible for the development and determination of the performance characteristics for Cxbladder. Because Cxbladder is a Laboratory Developed Test (LDT), Cxbladder has not been cleared or approved by the US Food and Drug Administration (FDA).

Diagnosing bladder cancer

Drs Sia Daneshmand and Joseph DiTrolio discuss the guidelines, issues and technologies for diagnosing UC in patients presenting with hematuria in primary care.

Diagnosing bladder cancer
Diagnosing bladder cancer